Odyssey Therapeutics, Inc. (ODTX) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

40/ 100

GoAI Score

Sell

Valuation

38

Expensive

Sentiment

56

Mixed

Risk

52

Elevated Risk

Momentum

42

Neutral

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Industry: Biotechnology
Sector: Healthcare
Headquarters: US

Market position

Day range

Current $18.12

$17.14$18.38

52-week range

Current $18.12

$15.10$29.05

Open: $17.83
Previous close: $18.08
Volume: 414.21K
Market cap: 870.33M USD
50-day average: $22.5526; -19.65% below average
200-day average: $19.876; -8.83% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 437.98M USD
P/E (TTM): -7.11×
P/B (TTM): 1.3×
P/S (TTM): 0×
EV / EBITDA: -3.03×
Earnings yield: -32.85%
Free cash flow yield: -28.88%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: 30.44%
Return on assets: -55.10%
Return on invested capital: -64.44%

Financial health

Debt / equity: 0.06×
Current ratio: 7.2×

Financial statements

Financial statements: Income statement
Metric (USD)	FY2025
Revenue	2.98M USD
Gross profit	2.98M USD
Research and development	126.62M USD
Selling, general, and administrative	37.52M USD
Operating expenses	164.13M USD
Interest income	6.35M USD
Interest expense	17K USD
Depreciation and amortization	4.91M USD
Operating income	−161.16M USD
Net income	−148.65M USD

Company facts updated Oct 9, 2026.

Earnings

EPS beat rate: 0%; 0 beats, 2 misses, 0 met estimates
Average EPS surprise: -258.04%; 2 comparable reports
Latest EPS result: -1.74; Estimate -1.61 · Miss by 8.07%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$39.00

115.23% upside

Past 12 months12-month forecastHigh $44.00Average $39.00Low $30.00

Recent analyst actions

2 institutions

JP MorganmaintainOverweightAug 7, 2026

OppenheimermaintainOutperformJun 18, 2026

ODTX news

globenewswire.comOct 6, 2026

Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026

Company to host conference call and webcast following the presentation on Tuesday, October 20, at 8:00 a.m. EDT BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the…

Read source

defenseworld.netOct 5, 2026

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Consensus Target Price of $35.75 According to Brokerages

Shares of Odyssey Therapeutics, Inc. (NASDAQ: ODTX - Get Free Report) have earned an average rating of "Moderate Buy" from the eight research firms that are covering the company, MarketBeat Ratings reports. One…

Read source

seekingalpha.comSep 16, 2026

Odyssey Therapeutics, Inc. (ODTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Read source

globenewswire.comSep 16, 2026

Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum

BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients…

Read source

globenewswire.comAug 26, 2026

Odyssey Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients…

Read source